(Press-News.org) JACKSONVILLE, Fla. — A potentially powerful new approach to treating two lethal metastatic cancers — triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer — has been discovered by researchers at Mayo Clinic in Florida. In the online issue of Molecular Cancer Therapeutics, they report that two drugs, romidepsin and decitabine, work cooperatively to activate a potent tumor suppressor gene that is silenced in these cancers. Once the gene, secreted frizzled related protein one or sFRP1, went to work after the drugs were used, the laboratory tumor cells stopped growing and died.
Both drugs are approved by the Food and Drug Administration to treat blood cancer and are being tested individually in numerous solid cancers in which sFRP1 is disabled. This study was the first to test the use of both in these metastatic cancers linked to sFRP1, and the results are very encouraging, says senior investigator John Copland, Ph.D., a Mayo Clinic molecular biologist.
"We now have the basis for a clinical trial aimed at providing effective therapy for two drug-resistant cancers and perhaps many more tumor types in the future," Dr. Copland says. In addition to breast and kidney cancer, sFRP1 is disabled in colon, ovarian, lung, liver and other tumor types.
Dr. Copland and his colleagues earlier discovered that sFRP1 was silenced in certain cancers. This new work demonstrates that its expression can be restored by romidepsin, which is a histone deacetylase inhibitor, and decitabine, a methyltranferase inhibitor. Both are epigenetic drugs, modifying genes in a way that affects whether they are turned on or off.
"Individually, each drug did not induce any form of cell death but, together, they killed all of the different cell lines of kidney and triple negative breast cancer that we tested in the laboratory," says lead investigator Simon Cooper, Ph.D., a Mayo Clinic molecular biologist who specializes in renal cancer.
The two cancers affect up to 80,000 Americans each year and therapies to treat both, especially when they are advanced, have been very limited, says co-author Edith Perez, M.D., deputy director of Mayo Clinic Cancer Center.
"But now, not only do we have a very promising lead on future therapy, but if this combination treatment works as we hope it does, we will have a biomarker to be able to test which patients might benefit the most," she says. "In other words, a biopsy test could identify patients whose tumors had lost sFRP1 function."
The approach to finding this potential new treatment strategy is novel, adds oncologist Michael Menefee, M.D., who is also a study co-author.
"This type of interdisciplinary preclinical research effort is important, not only because of the value of the science, but also because the drugs are already in the clinic and that will facilitate translational efforts and hopefully confirm the preclinical findings in patients with advanced malignancies," he said.
INFORMATION:
Other study co-authors include Christina A. von Roemeling; Kylie H. Jang; Laura A. Marlow, M.S.; Stefan K. Grebe, M.D.; Han W. Tun, M.D.; and Gerardo Colon-Otero, M.D.
The study was funded in part by grants from the National Institutes of Health, the David & Lois Stulberg Endowed Fund for Kidney Cancer Research, the Breast Cancer Research Foundation, James C. and Sarah K. Kennedy Mayo Clinic Research Career Development Award for Clinicians, The Brenda E. and Roger S. Luca Family Endowment at The Tallahassee Memorial HealthCare Foundation, RITA Foundation (Research Is The Answer), Scheidel Foundation, and a grant for rare cancers from Dr. Ellis and Dona Brunton.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.
Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
2012-08-01
ELSE PRESS RELEASES FROM THIS DATE:
As a man's belt size increases, so does his risk of sexual and urinary dysfunction
2012-08-01
NEW YORK (July 31, 2012) -- As a man's waistline grows, so can his experience with sexual dysfunction and frequent urination, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The study, published in the August issue of the British Journal of Urology International (BJUI), is the first to comprehensively show that obesity in men affects not just their hearts and metabolism, but also their sexual and urinary health.
"The findings demonstrate that obesity in men -- part of a growing global epidemic -- affects their well-being in profound ways," ...
'Superbird' stuns researchers
2012-08-01
A team of researchers from the Wildlife Conservation Society (WCS) and the National Research Council of Argentina recently fitted a South American sea bird called an imperial cormorant with a small camera, then watched stunned as it became "superbird" – diving 150 feet underwater in 40 seconds, feeding on the ocean floor for 80 seconds where it eventually caught a snakelike fish, before returning to the surface 40 seconds later.
This is the first time researchers have been able to watch first-hand the amazing feeding techniques of these fascinating birds, which occur ...
Study finds people have difficulty controlling multiple chronic conditions
2012-08-01
DENVER, July 31, 2012 – Most people who have diabetes, high blood pressure, and high cholesterol have difficultly managing all three conditions; indeed, success is fleeting for those who do manage all three, according to a Kaiser Permanente Institute for Health Research study that appears online in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.
The study of close to 29,000 individuals enrolled at Kaiser Permanente Colorado and Denver Health found that only 30.3 percent at Kaiser Permanente and 16.2 percent of individuals at Denver ...
Protein involved in DNA replication, centrosome regulation linked to dwarfism, small brain size
2012-08-01
Cold Spring Harbor, NY – Research published Aug. 1 by scientists at Cold Spring Harbor Laboratory (CSHL) links gene mutations found in some patients with Meier-Gorlin syndrome (MGS) with specific cellular dysfunctions that are thought to give rise to a particularly extreme version of dwarfism, small brain size, and other manifestations of abnormal growth which generally characterize that rare condition.
Although only 53 cases of Meier-Gorlin syndrome have been reported in the medical literature since the first patient was described in 1959, it is a malady whose mechanisms ...
AGU journal highlights -- 31 July 2012
2012-08-01
The following highlights summarize research papers that have been recently published in Water Resources Research (WRR),Geophysical Research-Atmospheres (JGR-D), Journal of Geophysical Research-Space Physics (JGR-A), Journal of Geophysical Research-Biogeosciences (JGR-G), and Journal of Geophysical Research-Oceans (JGR-C).
In this release:
1. The random walk of pollutants through river catchments
2. Atmospheric CO2 drove climate change during longest interglacial
3. Shear layers in solar winds affect Earth's magnetosphere
4. Dams impact carbon dynamics in U.S. rivers
5. ...
Wayne State research team finds possible clue to progression of MS
2012-08-01
DETROIT -- Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease's progression. The finding could lead to new targeted therapies for MS treatment.
B cells, said Robert Lisak, M.D., professor of neurology at Wayne State and lead author of the study, are a subset of lymphocytes (a type of circulating white blood cell) that mature to become plasma cells and produce immunoglobulins, proteins that ...
Weight-loss clinic drop-out rates are a huge barrier to treating obesity
2012-08-01
More than 1.7 billion people worldwide may be classified as overweight and need appropriate medical or surgical treatment with the goal of sustainable weight loss. But for weight management programs to be effective, patients must complete them, states a study published in the Canadian Journal of Surgery (CJS) that analyzed drop-out rates and predictors of attrition within a publicly-funded adult weight management program.
Researchers from the Department of Surgery at the University of Alberta and the Centre for the Advancement of Minimally Invasive Surgery at the Royal ...
Research identifies a promising new therapeutic target for aggressive breast cancer
2012-08-01
Scientists at Western University have identified a new therapeutic target for advanced breast cancer which has shown tremendous promise in mouse models. The study led by Lynne-Marie Postovit of Western's Schulich School of Medicine & Dentistry looked at a protein called Nodal that is primarily found in embryonic or stem cells. Postovit discovered high levels of this protein in aggressive breast cancer tumors. Nodal was found to promote vascularization in the tumor, providing nutrients and oxygen to help it grow and spread. The research is published online in the journal ...
JAAOS study highlights success of nerve transfer surgery
2012-08-01
Because many physicians are unaware of nerve transfer surgery, some patients suffer long-term impairment from nerve injuries that could have been fixed.
A study in the August issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) by Hospital for Special Surgery researchers aims to raise awareness of this type of surgery among health care providers. In recent years, great strides have been made in nerve transfer surgery, allowing many patients with a nerve injury in their upper extremity to have a remarkable recovery and improved functional outcomes. ...
Sleep affects potency of vaccines
2012-08-01
As moms have always known, a good night's sleep is crucial to good health -- and now a new study led by a UCSF researcher shows that poor sleep can reduce the effectiveness of vaccines.
The study is the first performed outside a sleep laboratory to show that sleep duration is directly tied to vaccine immune response, the authors said.
The study, conducted while the UCSF researcher was a doctoral student at the University of Pittsburgh, will appear in the August issue of the journal "SLEEP."
"With the emergence of our 24-hour lifestyle, longer working hours, and ...